文献速递小儿眼科与斜弱视

双眼分视数字疗法治疗弱视的随机对照试验

Randomized Controlled Trial of a Dichoptic Digital Therapeutic for Amblyopia.
PubMed 文献 · Ophthalmology · 2021-09-14

这项在美国21个学术和社区站点开展的3期随机对照试验纳入105名4至7岁弱视儿童,按1:1随机分为治疗组和对照组。治疗组每天在家使用双眼分视数字疗法1小时、每周6天并全天戴镜,对照组仅全天戴镜。12周时治疗组弱视眼视力较基线提高1.8行(95%CI 1.4-2.3行),对照组提高0.8行(95%CI 0.4-1.3行),组间差异1.0行(P=0.0011),研究因成功提前终止,未报告严重不良事件。

要点

  • 双眼分视数字疗法联合全天戴镜较单独戴镜在12周时多提高约1.0行弱视眼视力。
  • 治疗组弱视眼视力较基线提高1.8行,对照组提高0.8行。
  • 研究未报告严重不良事件,支持该疗法在临床实践中的治疗价值。

核心结论

  • 双眼分视数字疗法是弱视的有效治疗,支持其在临床实践中的应用价值。
  • 未来研究应将该疗法与其他方法比较,并在更多患者人群中评估。

研究设计与样本

  • 3期随机对照试验,在美国21个学术和社区站点开展。
  • 纳入105名4至7岁弱视儿童,按1:1随机分为治疗组(51名)和对照组(54名),按站点分层。
  • 治疗组每天在家使用双眼分视数字疗法1小时、每周6天并全天戴镜,对照组仅全天戴镜。
  • 主要疗效指标为12周时弱视眼视力较基线的变化,由设盲检查者测量,采用意向性治疗人群分析。

主要发现

  • 12周时治疗组弱视眼视力较基线提高1.8行(95%CI 1.4-2.3行;n=45)。
  • 12周时对照组弱视眼视力较基线提高0.8行(95%CI 0.4-1.3行;n=45)。
  • 计划期中分析显示组间差异1.0行(P=0.0011;96.14%CI 0.33-1.63行),研究按方案因成功提前终止。
  • 未报告严重不良事件。

关键数值与推荐

  • 主要疗效终点为12周时弱视眼视力较基线的变化,由设盲检查者测量。
  • 期中分析校正α=0.0193,组间差异1.0行(P=0.0011;96.14%CI 0.33-1.63行)。

临床怎么用

  • 对4至7岁弱视儿童,可考虑在全程戴镜基础上加用双眼分视数字疗法,每天1小时、每周6天。
  • 治疗12周可使弱视眼视力较单独戴镜额外提高约1.0行。

局限性

  • 研究未与其他弱视治疗方法进行比较。
  • 研究对象仅限4至7岁儿童,其他患者人群需进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Digital therapeutics are a new class of interventions that are software driven and are intended to treat various conditions. We developed and evaluated a dichoptic digital therapeutic for amblyopia, a neurodevelopmental disorder for which current treatments may be limited by poor adherence and residual vision deficits. DESIGN: Randomized controlled trial. PARTICIPANTS: One hundred five children 4 to 7 years of age with amblyopia were enrolled at 21 academic and community sites in the United States. Participants were randomized 1:1 to the treatment or comparison group, stratified by site. METHODS: We conducted a phase 3 randomized controlled trial to evaluate the safety and efficacy of a dichoptic digital therapeutic for amblyopia. Participants in the treatment group used the therapeutic at home for 1 hour per day, 6 days per week and wore glasses full-time. Participants in the comparison group continued wearing glasses full-time alone. MAIN OUTCOME MEASURES: The primary efficacy outcome was change in amblyopic eye visual acuity (VA) from baseline at 12 weeks, and VA was measured by masked examiners. Safety was evaluated using the frequency and severity of study-related adverse events. Primary analyses were conducted using the intention-to-treat population. RESULTS: Between January 16, 2019, and January 15, 2020, 105 participants were enrolled; 51 were randomized to the treatment group and 54 were randomized to the comparison group. At 12 weeks, amblyopic eye VA improved by 1.8 lines (95% confidence interval [CI], 1.4-2.3 lines; n = 45) in the treatment group and by 0.8 lines (95% CI, 0.4-1.3 lines; n = 45) in the comparison group. At the planned interim analysis (adjusted α = 0.0193), the difference between groups was significant (1.0 lines; P = 0.0011; 96.14% CI, 0.33-1.63 lines) and the study was stopped early for success, according to the protocol. No serious adverse events were reported. CONCLUSIONS: Our findings support the value of the therapeutic in clinical practice as an effective treatment. Future studies should evaluate the therapeutic compared with other methods and in additional patient populations.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Xiao S, Angjeli E, Wu HC, et al. Randomized Controlled Trial of a Dichoptic Digital Therapeutic for Amblyopia. Ophthalmology. 2021. PMID: 34534556. doi:10.1016/j.ophtha.2021.09.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。